EUVIMEDDescoperă EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Melanoma genomics – will we go beyond BRAF in clinics?

Justyna Mirek, Wiesław Bal, Magdalena Olbryt

Journal of Cancer Research and Clinical Oncology · 2024-09-28 · 150 (9)

DOI: 10.1007/s00432-024-05957-2 ↗

At a glance

Übersichtsarbeit in Journal of Cancer Research and Clinical Oncology, published online on 2024-09-28. Written by Justyna Mirek and 2 co-authors. Institution: Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gli…. Major MEDLINE topics: Melanoma, Proto-Oncogene Proteins B-raf, Genomics. Cited 15 times so far (Crossref); 100 references. The full text is freely available (open access, CC BY 4.0).

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

In the era of next-generation sequencing, the genetic background of cancer, including melanoma, appears to be thoroughly established. However, evaluating the oncogene BRAF mutation in codon V600 is still the only companion diagnostic genomic test commonly implemented in clinics for molecularly targeted treatment of advanced melanoma. Are we wasting the collected genomic data? Will we implement our current genomic knowledge of melanoma in clinics soon? This question is rather urgent because new therapeutic targets and biomarkers are needed to implement more personalized, patient-tailored therapy in clinics. Here, we provide an update on the molecular background of melanoma, including a description of four already established molecular subtypes: BRAF+, NRAS+, NF1+, and triple WT, as well as relatively new NGS-derived melanoma genes such as PREX2 , ERBB4 , PPP6C , FBXW7 , PIK3CA , and IDH1 . We also present a comparison of genomic profiles obtained in recent years with a focus on the most common melanoma genes. Finally, we propose our melanoma gene panel consisting of 22 genes that, in our opinion, are “must-have” genes in both melanoma-specific genomic tests and pan-cancer tests established to improve the treatment of melanoma further.

Subjects

MeSH terms (MEDLINE)

MelanomaProto-Oncogene Proteins B-rafGenomicsHumansMutationHigh-Throughput Nucleotide SequencingBiomarkers, TumorSkin Neoplasms

Author keywords

BRAFGenomic testingGenomicsMelanomaNGS

Substances

Proto-Oncogene Proteins B-rafBRAF protein, humanBiomarkers, Tumor

Authors and institutions

  • Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, 44-101, Poland.
  • Chemotherapy Day Unit, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, 44-101, Poland.
  • Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, 44-101, Poland. magdalena.olbryt@gliwice.nio.gov.pl.

Cite

APA

Mirek, J., Bal, W., & Olbryt, M. (2024). Melanoma genomics – will we go beyond BRAF in clinics?. Journal of Cancer Research and Clinical Oncology, 150(9). https://doi.org/10.1007/s00432-024-05957-2

Vancouver

Mirek J, Bal W, Olbryt M. Melanoma genomics – will we go beyond BRAF in clinics?. Journal of Cancer Research and Clinical Oncology. 2024;150(9). doi:10.1007/s00432-024-05957-2

BibTeX
@article{Mirek2024,
  author = {Mirek, Justyna and Bal, Wiesław and Olbryt, Magdalena},
  title = {Melanoma genomics – will we go beyond BRAF in clinics?},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  volume = {150},
  number = {9},
  doi = {10.1007/s00432-024-05957-2}
}
Start for free →